| dc.contributor.author | Singhvi, Gautam | |
| dc.date.accessioned | 2024-01-09T07:13:30Z | |
| dc.date.available | 2024-01-09T07:13:30Z | |
| dc.date.issued | 2022-04 | |
| dc.identifier.uri | https://www.tandfonline.com/doi/full/10.1080/17425247.2022.2053674 | |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13741 | |
| dc.description.abstract | The current drug therapies for treating rheumatoid arthritis (RA) include nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, or biological products designed to mitigate the symptoms of the disease. These therapies with conventional delivery systems possess limitations such as lack of selectivity and adverse effects in the extra-articular tissues. Microneedles-based transdermal drug delivery gained huge attention that can overcome the limitations associated with conventional preparations. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Taylor & Francis | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | Microneedles | en_US |
| dc.subject | Rheumatoid arthritis | en_US |
| dc.subject | Skin layers | en_US |
| dc.subject | Transdermal delivery | en_US |
| dc.subject | Pain | en_US |
| dc.title | Emerging trends in microneedle-based drug delivery strategies for the treatment of rheumatoid arthritis | en_US |
| dc.type | Article | en_US |
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||